An overview of ozanimod as a therapeutic option for adults with moderate-to-severe active ulcerative colitis.

Rowan, Catherine; Ungaro, Ryan; Mehandru, Saurabh; Colombel, Jean-Frederic

Rowan, Catherine; Ungaro, Ryan; Mehandru, Saurabh; Colombel, Jean-Frederic.

Afiliação

Rowan C; Henry D. Janowitz Division of Gastroenterology, Susan and Leonard Feinstein Inflammatory Bowel Disease Center, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Ungaro R; Henry D. Janowitz Division of Gastroenterology, Susan and Leonard Feinstein Inflammatory Bowel Disease Center, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Mehandru S; Henry D. Janowitz Division of Gastroenterology, Susan and Leonard Feinstein Inflammatory Bowel Disease Center, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Colombel JF; Henry D. Janowitz Division of Gastroenterology, Susan and Leonard Feinstein Inflammatory Bowel Disease Center, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Expert Opin Pharmacother ; 23(8): 893-904, 2022 Jun.

Article em En | MEDLINE | ID: mdl-35503955

Assuntos

Colite Ulcerativa; Adulto; Colite Ulcerativa/tratamento farmacológico; Humanos; Fatores Imunológicos/uso terapêutico; Indanos/uso terapêutico; Oxidiazóis/efeitos adversos; Receptores de Lisoesfingolipídeo; Receptores de Esfingosina-1-Fosfato

Palavras-chave

Inflammatory bowel disease; ozanimod; small molecules; sphingosine-1-phosphate receptor modulators; ulcerative colitis

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Colite Ulcerativa Limite: Adult / Humans Idioma: En Revista: Expert Opin Pharmacother Assunto da revista: FARMACOLOGIA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google